Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
J. B. Chemicals & Pharmaceuticals Limited (JBCHEPHARM.NS)
Mumbai, IN
J. B. Chemicals & Pharmaceuticals Limited, an enterprise founded in Mumbai, India, in 1976, specializes in the development, production, and global distribution of diverse pharmaceutical formulations, herbal remedies, and active pharmaceutical ingredients. Among its prominent product offerings are Cilnidipine, Ranitidine, and Metronidazole. Beyond its own brands, the company extends comprehensive contract manufacturing services, covering an extensive spectrum of dosage forms such as tablets, various lozenge types, injectables, gels, creams, ointments, liquid herbal syrups, and capsules. The firm further contributes to diagnostic medicine by supplying contrast agents for advanced imaging techniques like X-ray, MRI, and ultrasound. Its therapeutic expertise encompasses a broad range of medical fields, including gastroenterology, hypertension, diabetes, dermatology, nephrology, wound care, anti-infectives, and pharmacovigilance.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42% | -1.79% | +5.33% | +11.26% | +15.74% | +15.67% | +32.98% | +105.64% | +203.92% | +1,534.24% | +18,347.85% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 5 | -1 |
| Hold | 3 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+7.4% ★ Q1'26: +1.2% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+7.0% Q1'26: -31.1% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+13.1% Q1'26: +34.9% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.3% ★ Q1'26: +16.7% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.0% ★ Q1'26: +13.9% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.6% Q1'26: +1.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.00× ★ Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2003 actual |
Mar 2011 actual |
Mar 2014 actual |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
Mar 2022 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 6 Rev. Ana. 8 EPS Ana. |
Mar 2027 7 Rev. Ana. 8 EPS Ana. |
Mar 2028 2 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
2.96B
est.
|
8.91B
est: 8.74B (+1.9%)
|
9.38B
est: 9.95B (-5.8%)
|
10.47B
est: 10.79B (-3.0%)
|
11.67B
est: 12.02B (-2.9%)
|
13.09B
est: 12.75B (+2.7%)
|
13.82B
est: 14.45B (-4.3%)
|
16.08B
est: 15.39B (+4.4%)
|
17.41B
est: 17.60B (-1.1%)
|
20.19B
est: 20.14B (+0.3%)
|
24.24B
est: 24.08B (+0.7%)
|
31.17B
est: 31.42B (-0.8%)
|
34.48B
est: 35.01B (-1.5%)
|
38.62B
est: 39.44B (-2.1%)
|
42.99B
42.84B – 43.25B
+9.0% YoY
|
47.97B
47.34B – 48.71B
+11.6% YoY
|
53.43B
52.73B – 54.26B
+11.4% YoY
|
| EBITDA |
789.21M
est.
|
1.99B
est: 2.04B (-2.7%)
|
1.18B
est: 2.32B (-49.3%)
|
1.88B
est: 1.45B (+29.1%)
|
2.64B
est: 2.06B (+27.7%)
|
2.82B
est: 3.00B (-6.0%)
|
2.54B
est: 2.33B (+8.8%)
|
3.47B
est: 4.69B (-26.1%)
|
4.18B
est: 4.28B (-2.3%)
|
6.72B
est: 4.47B (+50.3%)
|
5.83B
est: 4.97B (+17.2%)
|
7.05B
est: 5.68B (+24.2%)
|
9.33B
est: 6.43B (+45.1%)
|
10.69B
est: 7.27B (+47.1%)
|
11.58B
11.54B – 11.65B
+59.4% YoY
|
12.93B
12.76B – 13.13B
+11.6% YoY
|
14.40B
14.21B – 14.62B
+11.4% YoY
|
| EBIT |
680.05M
est.
|
1.76B
est: 1.55B (+13.6%)
|
898.54M
est: 1.76B (-49.0%)
|
1.49B
est: 618.15M (+140.9%)
|
2.22B
est: 1.72B (+28.9%)
|
2.35B
est: 1.76B (+33.6%)
|
1.97B
est: 1.36B (+44.5%)
|
2.91B
est: 2.74B (+6.5%)
|
3.52B
est: 2.80B (+25.4%)
|
6.04B
est: 3.33B (+81.2%)
|
5.10B
est: 3.70B (+37.8%)
|
5.91B
est: 4.23B (+39.7%)
|
7.95B
est: 4.79B (+65.9%)
|
8.98B
est: 7.21B (+24.6%)
|
9.99B
9.96B – 10.05B
+38.6% YoY
|
11.15B
11.00B – 11.32B
+11.6% YoY
|
12.42B
12.26B – 12.61B
+11.4% YoY
|
| Net Income |
977.75M
est.
|
1.39B
est: 1.42B (-1.7%)
|
614.96M
est: 1.61B (-61.9%)
|
1.00B
est: 686.22M (+46.3%)
|
1.63B
est: 1.14B (+42.4%)
|
1.84B
est: 1.66B (+11.0%)
|
1.38B
est: 1.36B (+1.6%)
|
1.93B
est: 2.35B (-17.5%)
|
2.72B
est: 2.19B (+24.2%)
|
4.48B
est: 2.94B (+52.2%)
|
3.85B
est: 3.27B (+17.9%)
|
4.10B
est: 3.73B (+9.8%)
|
5.53B
est: 4.23B (+30.6%)
|
6.60B
est: 7.07B (-6.7%)
|
8.30B
7.76B – 8.82B
+17.4% YoY
|
9.82B
9.07B – 10.22B
+18.4% YoY
|
11.96B
11.76B – 12.20B
+21.7% YoY
|
| SGA |
644.29M
est.
|
2.03B
est: 4.09B (-50.5%)
|
1.16B
est: 4.66B (-75.0%)
|
2.12B
est: 3.67B (-42.3%)
|
2.28B
est: 4.23B (-46.0%)
|
2.80B
est: 4.12B (-32.1%)
|
3.21B
est: 3.51B (-8.5%)
|
3.82B
est: 8.78B (-56.5%)
|
4.07B
est: 6.62B (-38.5%)
|
4.26B
est: 6.62B (-35.6%)
|
5.66B
est: 7.35B (-23.0%)
|
7.28B
est: 8.39B (-13.3%)
|
8.11B
est: 9.52B (-14.8%)
|
9.17B
est: 9.22B (-0.5%)
|
9.89B
9.86B – 9.95B
+7.3% YoY
|
11.04B
10.90B – 11.21B
+11.6% YoY
|
12.30B
12.14B – 12.49B
+11.4% YoY
|
| EPS |
6.16
est.
|
16.50
est: 16.01 (+3.0%)
|
3.63
est: 15.05 (-75.9%)
|
5.92
est: 8.02 (-26.2%)
|
19.16
est: 10.04 (+90.9%)
|
10.85
est: 9.95 (+9.0%)
|
8.24
est: 13.75 (-40.1%)
|
11.77
est: 11.05 (+6.5%)
|
17.10
est: 17.54 (-2.5%)
|
28.98
est: 27.96 (+3.7%)
|
24.93
est: 27.42 (-9.1%)
|
26.50
est: 27.97 (-5.3%)
|
35.66
est: 36.03 (-1.0%)
|
42.45
est: 43.20 (-1.7%)
|
52.30
48.89 – 55.55
+21.1% YoY
|
61.90
57.15 – 64.38
+18.4% YoY
|
75.36
74.09 – 76.88
+21.7% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Nikhil Ashokkumar Chopra | Chief Executive Officer | 78M | male |
| Bhagwat Singh Deora | Vice President of Finance & Accounts | — | male |
| Himanshu Ranvah | Vice President of Legal | — | male |
| Kaushal Solanki | Chief Financial Officer | — | male |
| Parmeshwar Bang | Executive Vice President of Operations of Daman | — | male |
| Pradeep Kumar Singh | President of Global Business | — | male |
| Sandeep Anil Phadnis | Vice President of Secretarial & Company Secretary and Compliance Officer | — | male |
| Sridhar Bharadwaj | Vice President of Human Resources & Administration | — | male |
| Suresh Amin | Assistant Vice President Human Resource | — | — |
| Alisher Djabbarov | Head of Representative Office - Tashkent & Uzbekistan | — | — |
| Suresh Bhise | Vice President of Information & Technology | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for JBCHEPHARM.NS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
